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background: Transcatheter aortic valve replacement (TAVR) has emerged as a therapeutic option for patients with symptomatic, severe aortic 
stenosis. Many of these patients have a pacemaker (PM) present before TAVR, or have one implanted as a consequence of the procedure. We 
investigated whether the presence of a PM was associated with adverse events in a large cohort of patients from The PARTNER Trial.
methods: The analysis included patients that underwent TAVR in the PARTNER randomized trial as well as the subsequent non-randomized 
continued access registries. Clinical and echocardiographic outcomes were compared between patients with PM (either preexisting or implanted 
after TAVR) and those without PM. Subgroup analysis based on left ventricular ejection fraction (LVEF) was performed.
results: Overall, PM was present in 759 of 2559 (29.7%) patients, including 586 (77.2%)with a preexisting PM and 173 (22.9%) with PM 
implantation after TAVR. Compared to those without PM, the PM patients were older (85.0 vs 84.2 years), more frequently male (61.1 vs 48.6%), 
had higher STS scores (11.8 vs 11.3), and had higher frequency of CAD (82.5 vs 75.8%)(all p < 0.01). At 1 year, the PM group had higher rates of all 
cause mortality (27.1 vs 20.8%, p < 0.001), rehospitalization (22.5 vs 18.2%, p = 0.02), and combined death/rehospitalization (39.7 vs 32.6%, p < 
0.001). By multivariate analysis, presence of a PM was an independent predictor of death at 1 year (HR 1.27, 95% CI 1.05, 1.53, p = 0.01). Patients 
with a PM had lower LVEF at 1 year compared to non-PM patients (48.8 vs 53.9, p < 0.001). Among those with depressed baseline LVEF (< 50%), PM 
patients had impaired recovery of LVEF after TAVR (Δ= 4.2 vs 7.4% for baseline LVEF 35 to 50, p = 0.001; Δ=11.0 vs 17.9% for baseline LVEF <35, p 
< 0.001).
conclusions: In The PARTNER Trial experience, TAVR patients with a PM had significantly increased mortality and rehospitalization at 1 year relative 
to patients without PM. PM patients also had lower LVEF at 1 year, primarily as a result of poorer recovery of LVEF after TAVR, particularly among 
those with baseline depressed LVEF. Ventricular dyssynchrony due to PM therapy may be mechanistically responsible for these findings.
